Gastric CancerPhase 4REPROG-RCTNCT07467174
RCT Comparing Reduced-port Robotic and Conventional Laparoscopic Subtotal Gastrectomy
A Phase 4 study testing conventional laparoscopy gastrectomy group (Port > 3) and reduced-port robotic group (Port ≤ 3) in people with Gastric Cancer, run by Yonsei University at 1 site in South Korea.
Trial summary
"Study objective The objective of this study is to evaluate whether reduced-port robotic subtotal gastrectomy demonstrates non-inferiority in safety, specifically regarding the incidence of postoperative complications, compared to conventional laparoscopic subtotal gastrectomy in patients with early gastric cancer. Read more about this study
- Who is it for?
- Ages 20 to 85 years
- Conditions the study is for
- Gastric Cancer
- What is being tested?
- conventional laparoscopy gastrectomy group (Port > 3) and reduced-port robotic group (Port ≤ 3)
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 538 participants
- Where
- 1 siteSouth Korea
- Study dates
- Apr 2026to Dec 2031
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients aged between 20 and 80 years diagnosed with early gastric cancer (cT1N0)
- Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Patients with an American Society of Anesthesiologists (ASA) physical status classification of Class I to III
- Patients with a histologically confirmed diagnosis of gastric adenocarcinoma by endoscopic biopsy prior to surgery
- Patients with early gastric cancer suspected to have submucosal invasion limited to less than the muscularis propria based on preoperative examinations
- Patients deemed eligible for distal subtotal gastrectomy based on preoperative assessment
- Patients who have received a full explanation of the study purpose and procedures, and who voluntarily sign the written informed consent approved by the Institutional Review Board (IRB)
Who cannot join
- Patients determined to have advanced gastric cancer rather than early gastric cancer based on preoperative endoscopy or computed tomography
- Patients with confirmed distant metastasis on preoperative examinations
- Patients with a history of previous gastrectomy
- Patients with complications from gastric cancer, such as significant obstruction or perforation
- Patients who have received chemotherapy or radiotherapy for the current gastric cancer diagnosis prior to surgery
- Patients who have undergone surgery or received chemotherapy or radiotherapy for another primary malignancy within the past 5 years (with the exception of adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix)
Show all 18Show fewer
- Vulnerable subjects, including individuals lacking decision-making capacity, pregnant women, or those planning pregnancy
- Patients who have participated in another clinical trial within the past 6 months or who are currently enrolled in another clinical trial
- Patients with active synchronous multiple primary malignancies
- Patients determined to have advanced gastric cancer rather than early gastric cancer based on preoperative endoscopy or computed tomography
- Patients with confirmed distant metastasis on preoperative examinations
- Patients with a history of previous gastrectomy
- Patients with complications from gastric cancer, such as significant obstruction or perforation
- Patients who have received chemotherapy or radiotherapy for the current gastric cancer diagnosis prior to surgery
- Patients who have undergone surgery or received chemotherapy or radiotherapy for another primary malignancy within the past 5 years (with the exception of adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix)
- Vulnerable subjects, including individuals lacking decision-making capacity, pregnant women, or those planning pregnancy
- Patients who have participated in another clinical trial within the past 6 months or who are currently enrolled in another clinical trial
- Patients with active synchronous multiple primary malignancies
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
South Korea1 site
Department of Gastrointestinal Surgery, Department of Surgery Severance Hospital, Yonsei University College of Medicine
Seoul
Hyung Il Kim, Prof., 010-2556-4986, cairus@yuhs.ac
About this study
Official title: Prospective Multicenter Randomized Controlled Trial Comparing Reduced-Port Robotic and Conventional Laparoscopic Subtotal Gastrectomy for Early Gastric Cancer (REPROG-RCT)
"Study objective The objective of this study is to evaluate whether reduced-port robotic subtotal gastrectomy demonstrates non-inferiority in safety, specifically regarding the incidence of postoperative complications, compared to conventional laparoscopic subtotal gastrectomy in patients with early gastric cancer. Additionally, the study aims to assess differences in efficacy between the two surgical approaches as secondary endpoints.
Study design overview This study is a multicenter, randomized controlled trial involving patients with early gastric cancer. Participants will be randomly assigned in a 1:1 ratio to either the reduced-port robotic surgery group or the conventional laparoscopic surgery group. Outcomes to be observed over a 30-day postoperative period include the incidence of complications, operative time, blood loss, pain levels, length of hospital stay, and quality of life.
Read more
Investigational Product/Medical Device Robotic surgical platform Laparoscopic surgical platform Target Sample Size and Rationale The study aims to demonstrate that reduced-port robotic subtotal gastrectomy (experimental group) is non-inferior to conventional laparoscopic subtotal gastrectomy (control group) with respect to the incidence of postoperative complications of grade ≥ 3.
Previous studies have reported that the complication rate for minimally invasive subtotal gastrectomy in early gastric cancer is approximately 4%.
For the non-inferiority test based on comparison of proportions, the following assumptions were used to calculate the required sample size:
- Complication rate in the control group (pC): 4%
- Complication rate in the experimental group (pT): 4%
- Non-inferiority margin (Δ): 5%
- Significance level (α): 2.5% (one-sided)
- Statistical power (1-β): 80%
- Allocation ratio: 1:1
- Expected dropout rate: 10%
Based on these assumptions, the calculated sample size is 242 patients per group. Considering a 10% dropout rate, the adjusted sample size is 269 patients per group, totaling 538 patients for the entire study.Inclusion:
Patients aged 20 to 80 years diagnosed with early gastric cancer (cT1N0) who are eligible for distal subtotal gastrectomy based on endoscopic or imaging findings.
Exclusion:
Presence of distant metastasis Diagnosis of advanced gastric cancer Suspected lymph node metastasis History of previous gastrectomy ASA physical status score > 3 Pregnancy or withdrawal of informed consent Randomization will be performed preoperatively using a web-based system. Surgical procedures will be conducted in accordance with standardized operative guidelines.
Follow-up assessments will be conducted at discharge, on postoperative day 30, and at 3 and 6 months postoperatively.
Endpoints
Primary Endpoint:
Incidence of postoperative complications of Clavien-Dindo grade ≥ III within 30 days after surgery
Secondary Endpoints:
Operative time Estimated blood loss Number of harvested lymph nodes Length of hospital stay Postoperative pain scores Quality of life (including wound-related discomfort and dietary function) Three-year disease-free survival rate Data analysis and statistical Methods Analyses will be conducted on an intention-to-treat (ITT) basis. Categorical variables will be analyzed using the χ² test or Fisher's exact test, as appropriate.
Continuous variables will be analyzed using either the t-test or the Mann-Whitney U test, depending on the distribution of the data.
Survival analyses will be performed using Kaplan-Meier curves and compared with the log-rank test.
Non-inferiority testing will be based on comparisons of 95% confidence intervals.
Read the detailed description
- Study Design (Study Groups, Randomization, Blinding, and Study Flow) 9.1 Eligibility Criteria for Participating Surgeons and Standardization and Quality Control of Surgical Procedures Prior to the initiation of this clinical trial, the REPROG-02QC study was conducted to identify and qualify surgeons eligible to participate. Only surgeons approved by the REPROG Committee, based on standardized criteria and assessment of surgical quality, are permitted to participate in this trial. Surgeons' clinical experience and proficiency in surgical techniques are evaluated before being allowed to participate in the randomized controlled trial (RCT). All participating surgeons must apply for participation and obtain approval from their respective Institutional Review Boards (IRBs).
They must also fulfill the following requirement:
Submission and completion of review for three to four unedited cases of reduced-port robotic gastrectomy, which will be evaluated by the committee for adequacy of lymph node dissection, surgical completeness, and intraoperative performance.
In addition, only surgeons affiliated with institutions performing at least 50 gastrectomies per year are eligible to apply for participation in this RCT.
The REPROG Committee will review the submitted videos, assign evaluation scores, and determine whether each surgeon is qualified.
Only surgeons who are officially qualified through this review process will be permitted to participate in the randomization phase of the RCT.
The submitted surgical videos are evaluated by a review committee composed of national and international experts in gastric cancer surgery. The evaluation criteria include adequacy of lymph node dissection, surgical completeness, tissue handling, visualization, and management of intraoperative bleeding. Only those surgeons who meet all the specified surgical evaluation criteria will be permitted to participate in the randomization phase of the trial. Surgeons may be required to undergo re-evaluation or submit additional cases if necessary. This process is designed to ensure quality control of surgical techniques throughout the REPROG study and to secure the internal validity of this multicenter trial.
10.2 Conduct of the Clinical Trial at Participating Institutions and Patient Enrollment The overall coordination and management of this clinical trial will be overseen by the Department of Gastrointestinal Surgery, Severance Hospital, Yonsei University College of Medicine (Coordinating Institution). Surgeons who decide to participate in the trial will receive the necessary documents for IRB submission from the designated study coordinator. Following IRB approval, patient enrollment may begin for those who meet the inclusion criteria. Patient registration and data management will be conducted using a web-based electronic case report form (e-CRF) system provided by Yonsei University Health System.
Patient Enrollment Procedure Eligible patients who meet all inclusion criteria and none of the exclusion criteria will be identified. After receiving a detailed explanation of the study, patients will be asked to sign the informed consent form. Subsequently, eligibility will be reconfirmed through a screening checklist on the web-based randomization system provided by Yonsei University. Upon confirmation, patients will be registered and randomized. The point of randomization coincides with the decision to proceed with surgery and the patient's agreement to participate in the clinical study. Enrollment will be competitive among participating institutions.
Patients will be withdrawn from the study in the following circumstances:
Withdrawal of consent after registration Failure to proceed with surgery within 30 days of registration If more than 30 days have passed, patients must undergo a re-evaluation of eligibility and provide new informed consent to participate in the trial. In the event of erroneous or duplicate registrations identified by individual investigators, the study coordinator must be contacted to correct the records. If identified by the study coordinator, the responsible investigator will be notified to rectify and re-register the patient. (This applies only to subjects in the screening phase before randomization.) The trial will close to enrollment once a total of 538 patients have been randomized and registered.
Randomization Method Randomization will be conducted separately for each participating investigator to ensure a 1:1 allocation ratio. A Baseline Number (BN) will be assigned in the order that patients provide informed consent. Eligible patients will then receive a sequential Allocation Number (AN) according to a pre-generated randomization table. Randomized block design will be used, with each investigator considered a stratification factor. Block sizes will not be disclosed to the investigators to preserve the randomness of allocation. Access to the web-based e-CRF will be secured via issued user IDs and passwords for each participating surgeon. Only authorized users with verified login credentials will be permitted to enter data into the system.
Study Groups
Group A (Conventional Laparoscopy Group):
Subtotal gastrectomy with D1+ lymph node dissection performed via the laparoscopic approach.
Group B (Reduced-Port Robotic Group):
Subtotal gastrectomy with D1+ lymph node dissection performed via the robotic approach using a reduced-port technique (involving three or fewer trocars).
DaVicnci SP robotic system will be used as long as the procedure is performed with three or fewer trocars in a reduced-port configuration that meets the study definition of the experimental group.
- Conditions
- Gastric Cancer
- Being tested
- conventional laparoscopy gastrectomy group (Port > 3), reduced-port robotic group (Port ≤ 3)
- Keywords
- gastrectomy, gastric cancer, robotic surgery, reduced-port surgery
- Medical subject headings
- Stomach Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
conventional laparoscopy gastrectomy group (Port > 3)Procedure or surgery
Subtotal gastrectomy with D1+ lymph node dissection performed via the laparoscopic approach.
reduced-port robotic group (Port ≤ 3)Procedure or surgery
Subtotal gastrectomy with D1+ lymph node dissection performed via the robotic approach using a reduced-port technique (involving three or fewer trocars).
| Study group | Role | What they receive |
|---|---|---|
| Convetional laparoscopy group | Active comparator | conventional laparoscopy gastrectomy group (Port > 3) Receives: Procedure: conventional laparoscopy gastrectomy group (Port > 3) |
| reduced-port robotic group | Active comparator | reduced-port robotic group (Port ≤ 3) Receives: Procedure: reduced-port robotic group (Port ≤ 3) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of postoperative complications of Clavien-Dindo grade ≥ III within 30 days after surgery
To verify the non-inferiority of reduced-port robotic subtotal gastrectomy compared to conventional laparoscopic subtotal gastrectomy in terms of the incidence of Clavien-Dindo grade III or higher postoperative complications occurring within 30 days after surgery.
Measured: postoperative 30 days
Secondary outcomes (12)
Postoperative complications (both early complications within 30 days and late complications thereafter)
Postoperative complications (both early complications within 30 days and late complications thereafter)
Measured: postoperative 30days, 90 days, 6months, 1year, 3 years
Postoperative mortality (all-cause mortality within 90 days after surgery)
Postoperative mortality (all-cause mortality within 90 days after surgery)
Measured: 90 days
Postoperative Pain Score
Pain intensity assessed using the Visual Analog Scale (VAS). Unit of Measure VAS score (0-10)
Measured: postoperative 30days, 90 days, 6months, 1year, 3 years
Postoperative Inflammatory Marker - C-Reactive Protein
Serum C-reactive protein level measured to assess postoperative inflammatory response.
Measured: postoperative 30days, 90 days, 6months, 1year, 3 years
Length of postoperative hospital stay
Measured: postoperative 30days, 90 days, 6months, 1year, 3 years
Time to Early Ambulation
Time from surgery to first ambulation.
Measured: perioperative
Time to Initiation of Oral Intake
Time from surgery to first oral intake.
Measured: perioperative
Postoperative Quality of Life Assessed by EORTC QLQ-C30
Quality of life will be assessed using the EORTC QLQ-C30, a validated questionnaire evaluating global health status, functional domains, and symptom scales.
Measured: postoperative 30days, 90 days, 6months, 1year, 3 years
Standard surgical outcomes checklist (resection margins, number of harvested lymph nodes, rate of readmission)
Standard surgical outcomes checklist (resection margins, number of harvested lymph nodes, rate of readmission, etc.)
Measured: postoperative 30days, 90 days, 6months, 1year, 3 years
Three-year Disease-Free Survival (DFS)
Disease-free survival defined as the time from surgery to the first documented recurrence of disease or death from any cause. DFS rates will be assessed at postoperative 30 days, 90 days, 6 months, 1 year, and 3 years.
Measured: postoperative 30days, 90 days, 6months, 1year, 3 years
Wound Satisfaction Score
Patient satisfaction with the surgical wound will be assessed using a postoperative wound satisfaction questionnaire.
Measured: postoperative 30days, 90 days, 6months, 1year, 3 years
Three-year Overall Survival (OS)
Overall survival defined as the time from surgery to death from any cause. OS rates will be assessed at postoperative 30 days, 90 days, 6 months, 1 year, and 3 years.
Measured: postoperative 30days, 90 days, 6months, 1year, 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Mar 2026
- Study startApr 2026 (estimated)
- Primary completionDec 2031 (estimated)
- Study completionDec 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Gastric CancerStudies of the same condition, open and under way.
- More trials run by Yonsei UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 538 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Yonsei University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07467174
- Sponsor's protocol ID
- 1-2025-0061
- Acronym
- REPROG-RCT
- Status last verified
- Mar 2026
- First submitted
- 21 Dec 2025
- Last updated
- 12 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Paterson JM, Smith SM, Simpson J, Grace OC, Sosunov AA, Bell JE, Antoni FA. Characterisation of human adenylyl cyclase IX reveals inhibition by Ca(2+)/Calcineurin and differential mRNA plyadenylation. J Neurochem. 2000 Oct;75(4):1358-67. doi: 10.1046/j.1471-4159.2000.0751358.x.
PubMed 10987815
Study at a glance
From the registry record, last updated by the sponsor on 12 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Multicenter Randomized Controlled Trial Comparing Reduced-Port Robotic and Conventional Laparoscopic Subtotal Gastrectomy for Early Gastric Cancer (REPROG-RCT)
- ClinicalTrials.gov ID
- NCT07467174
- Acronym / sponsor ID
- REPROG-RCT / 1-2025-0061
- Conditions
- Gastric Cancer
- Keywords
- gastrectomy, gastric cancer, robotic surgery, reduced-port surgery
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 538 participants (estimated)
- Lead sponsor
- Yonsei UniversityUniversity, hospital or other
- Study start
- Apr 2026 (estimated)
- Primary completion
- Dec 2031 (estimated)
- Study completion
- Dec 2031 (estimated)
- First posted
- 12 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
"Study objective The objective of this study is to evaluate whether reduced-port robotic subtotal gastrectomy demonstrates non-inferiority in safety, specifically regarding the incidence of postoperative complications, compared to conventional laparoscopic subtotal gastrectomy in patients with early gastric cancer. Additionally, the study aims to assess differences in efficacy between the two surgical approaches as secondary endpoints.
Study design overview This study is a multicenter, randomized controlled trial involving patients with early gastric cancer. Participants will be randomly assigned in a 1:1 ratio to either the reduced-port robotic surgery group or the conventional laparoscopic surgery group. Outcomes to be observed over a 30-day postoperative period include the incidence of complications, operative time, blood loss, pain levels, length of hospital stay, and quality of life.
Investigational Product/Medical Device Robotic surgical platform Laparoscopic surgical platform Target Sample Size and Rationale The study aims to demonstrate that reduced-port robotic subtotal gastrectomy (experimental group) is non-inferior to conventional laparoscopic subtotal gastrectomy (control group) with respect to the incidence of postoperative complications of grade ≥ 3.
Previous studies have reported that the complication rate for minimally invasive subtotal gastrectomy in early gastric cancer is approximately 4%.
For the non-inferiority test based on comparison of proportions, the following assumptions were used to calculate the required sample size:
- Complication rate in the control group (pC): 4%
- Complication rate in the experimental group (pT): 4%
- Non-inferiority margin (Δ): 5%
- Significance level (α): 2.5% (one-sided)
- Statistical power (1-β): 80%
- Allocation ratio: 1:1
- Expected dropout rate: 10%
Based on these assumptions, the calculated sample size is 242 patients per group. Considering a 10% dropout rate, the adjusted sample size is 269 patients per group, totaling 538 patients for the entire study.Inclusion:
Patients aged 20 to 80 years diagnosed with early gastric cancer (cT1N0) who are eligible for distal subtotal gastrectomy based on endoscopic or imaging findings.
Exclusion:
Presence of distant metastasis Diagnosis of advanced gastric cancer Suspected lymph node metastasis History of previous gastrectomy ASA physical status score > 3 Pregnancy or withdrawal of informed consent Randomization will be performed preoperatively using a web-based system. Surgical procedures will be conducted in accordance with standardized operative guidelines.
Follow-up assessments will be conducted at discharge, on postoperative day 30, and at 3 and 6 months postoperatively.
Endpoints
Primary Endpoint:
Incidence of postoperative complications of Clavien-Dindo grade ≥ III within 30 days after surgery
Secondary Endpoints:
Operative time Estimated blood loss Number of harvested lymph nodes Length of hospital stay Postoperative pain scores Quality of life (including wound-related discomfort and dietary function) Three-year disease-free survival rate Data analysis and statistical Methods Analyses will be conducted on an intention-to-treat (ITT) basis. Categorical variables will be analyzed using the χ² test or Fisher's exact test, as appropriate.
Continuous variables will be analyzed using either the t-test or the Mann-Whitney U test, depending on the distribution of the data.
Survival analyses will be performed using Kaplan-Meier curves and compared with the log-rank test.
Non-inferiority testing will be based on comparisons of 95% confidence intervals.
Detailed description
- Study Design (Study Groups, Randomization, Blinding, and Study Flow) 9.1 Eligibility Criteria for Participating Surgeons and Standardization and Quality Control of Surgical Procedures Prior to the initiation of this clinical trial, the REPROG-02QC study was conducted to identify and qualify surgeons eligible to participate. Only surgeons approved by the REPROG Committee, based on standardized criteria and assessment of surgical quality, are permitted to participate in this trial. Surgeons' clinical experience and proficiency in surgical techniques are evaluated before being allowed to participate in the randomized controlled trial (RCT). All participating surgeons must apply for participation and obtain approval from their respective Institutional Review Boards (IRBs).
They must also fulfill the following requirement:
Submission and completion of review for three to four unedited cases of reduced-port robotic gastrectomy, which will be evaluated by the committee for adequacy of lymph node dissection, surgical completeness, and intraoperative performance.
In addition, only surgeons affiliated with institutions performing at least 50 gastrectomies per year are eligible to apply for participation in this RCT.
The REPROG Committee will review the submitted videos, assign evaluation scores, and determine whether each surgeon is qualified.
Only surgeons who are officially qualified through this review process will be permitted to participate in the randomization phase of the RCT.
The submitted surgical videos are evaluated by a review committee composed of national and international experts in gastric cancer surgery. The evaluation criteria include adequacy of lymph node dissection, surgical completeness, tissue handling, visualization, and management of intraoperative bleeding. Only those surgeons who meet all the specified surgical evaluation criteria will be permitted to participate in the randomization phase of the trial. Surgeons may be required to undergo re-evaluation or submit additional cases if necessary. This process is designed to ensure quality control of surgical techniques throughout the REPROG study and to secure the internal validity of this multicenter trial.
10.2 Conduct of the Clinical Trial at Participating Institutions and Patient Enrollment The overall coordination and management of this clinical trial will be overseen by the Department of Gastrointestinal Surgery, Severance Hospital, Yonsei University College of Medicine (Coordinating Institution). Surgeons who decide to participate in the trial will receive the necessary documents for IRB submission from the designated study coordinator. Following IRB approval, patient enrollment may begin for those who meet the inclusion criteria. Patient registration and data management will be conducted using a web-based electronic case report form (e-CRF) system provided by Yonsei University Health System.
Patient Enrollment Procedure Eligible patients who meet all inclusion criteria and none of the exclusion criteria will be identified. After receiving a detailed explanation of the study, patients will be asked to sign the informed consent form. Subsequently, eligibility will be reconfirmed through a screening checklist on the web-based randomization system provided by Yonsei University. Upon confirmation, patients will be registered and randomized. The point of randomization coincides with the decision to proceed with surgery and the patient's agreement to participate in the clinical study. Enrollment will be competitive among participating institutions.
Patients will be withdrawn from the study in the following circumstances:
Withdrawal of consent after registration Failure to proceed with surgery within 30 days of registration If more than 30 days have passed, patients must undergo a re-evaluation of eligibility and provide new informed consent to participate in the trial. In the event of erroneous or duplicate registrations identified by individual investigators, the study coordinator must be contacted to correct the records. If identified by the study coordinator, the responsible investigator will be notified to rectify and re-register the patient. (This applies only to subjects in the screening phase before randomization.) The trial will close to enrollment once a total of 538 patients have been randomized and registered.
Randomization Method Randomization will be conducted separately for each participating investigator to ensure a 1:1 allocation ratio. A Baseline Number (BN) will be assigned in the order that patients provide informed consent. Eligible patients will then receive a sequential Allocation Number (AN) according to a pre-generated randomization table. Randomized block design will be used, with each investigator considered a stratification factor. Block sizes will not be disclosed to the investigators to preserve the randomness of allocation. Access to the web-based e-CRF will be secured via issued user IDs and passwords for each participating surgeon. Only authorized users with verified login credentials will be permitted to enter data into the system.
Study Groups
Group A (Conventional Laparoscopy Group):
Subtotal gastrectomy with D1+ lymph node dissection performed via the laparoscopic approach.
Group B (Reduced-Port Robotic Group):
Subtotal gastrectomy with D1+ lymph node dissection performed via the robotic approach using a reduced-port technique (involving three or fewer trocars).
DaVicnci SP robotic system will be used as long as the procedure is performed with three or fewer trocars in a reduced-port configuration that meets the study definition of the experimental group.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Convetional laparoscopy group | Active comparator | Procedure: conventional laparoscopy gastrectomy group (Port > 3)conventional laparoscopy gastrectomy group (Port > 3) |
| reduced-port robotic group | Active comparator | Procedure: reduced-port robotic group (Port ≤ 3)reduced-port robotic group (Port ≤ 3) |
Who may qualify
- Ages
- 20 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Patients aged between 20 and 80 years diagnosed with early gastric cancer (cT1N0)
- Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Patients with an American Society of Anesthesiologists (ASA) physical status classification of Class I to III
- Patients with a histologically confirmed diagnosis of gastric adenocarcinoma by endoscopic biopsy prior to surgery
- Patients with early gastric cancer suspected to have submucosal invasion limited to less than the muscularis propria based on preoperative examinations
Key exclusion criteria (18 listed)
- Patients determined to have advanced gastric cancer rather than early gastric cancer based on preoperative endoscopy or computed tomography
- Patients with confirmed distant metastasis on preoperative examinations
- Patients with a history of previous gastrectomy
- Patients with complications from gastric cancer, such as significant obstruction or perforation
- Patients who have received chemotherapy or radiotherapy for the current gastric cancer diagnosis prior to surgery
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| conventional laparoscopy gastrectomy group (Port > 3)Subtotal gastrectomy with D1+ lymph node dissection performed via the laparoscopic approach. | Procedure or surgery | Convetional laparoscopy group |
| reduced-port robotic group (Port ≤ 3)Subtotal gastrectomy with D1+ lymph node dissection performed via the robotic approach using a reduced-port technique (involving three or fewer trocars). | Procedure or surgery | reduced-port robotic group |
Primary outcome
Incidence of postoperative complications of Clavien-Dindo grade ≥ III within 30 days after surgery
Time frame: postoperative 30 days
To verify the non-inferiority of reduced-port robotic subtotal gastrectomy compared to conventional laparoscopic subtotal gastrectomy in terms of the incidence of Clavien-Dindo grade III or higher postoperative complications occurring within 30 days after surgery.
12 secondary outcomes
Postoperative complications (both early complications within 30 days and late complications thereafter)
Time frame: postoperative 30days, 90 days, 6months, 1year, 3 years
Postoperative mortality (all-cause mortality within 90 days after surgery)
Time frame: 90 days
Postoperative Pain Score
Time frame: postoperative 30days, 90 days, 6months, 1year, 3 years
Postoperative Inflammatory Marker - C-Reactive Protein
Time frame: postoperative 30days, 90 days, 6months, 1year, 3 years
Length of postoperative hospital stay
Time frame: postoperative 30days, 90 days, 6months, 1year, 3 years
Time to Early Ambulation
Time frame: perioperative
Time to Initiation of Oral Intake
Time frame: perioperative
Postoperative Quality of Life Assessed by EORTC QLQ-C30
Time frame: postoperative 30days, 90 days, 6months, 1year, 3 years
Standard surgical outcomes checklist (resection margins, number of harvested lymph nodes, rate of readmission)
Time frame: postoperative 30days, 90 days, 6months, 1year, 3 years
Three-year Disease-Free Survival (DFS)
Time frame: postoperative 30days, 90 days, 6months, 1year, 3 years
Wound Satisfaction Score
Time frame: postoperative 30days, 90 days, 6months, 1year, 3 years
Three-year Overall Survival (OS)
Time frame: postoperative 30days, 90 days, 6months, 1year, 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Mar 2026.
- Background: PubMed 10987815Paterson JM, Smith SM, Simpson J, Grace OC, Sosunov AA, Bell JE, Antoni FA. Characterisation of human adenylyl cyclase IX reveals inhibition by Ca(2+)/Calcineurin and differential mRNA plyadenylation. J Neurochem. 2000 Oct;75(4):1358-67. doi: 10.1046/j.1471-4159.2000.0751358.x.
- Individual participant dataSharing planned: Undecided
Related trials for Gastric Cancer
RecruitingPhase 2/3
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Recruiting
Individually Tailored, Supervised, Remote Exercise Intervention to Improve Physical Function for Stage I-III Gastroesophageal Cancer Survivors, PRECISE Trial
Clinical Stage I Esophageal Adenocarcinoma American Joint Committee on Cancer (AJCC) v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8
RecruitingPhase 2
Candonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
Stomach Neoplasms
Active, not recruiting
Telehealth for the Self-Management of Dietary Quality of Life in Patients After Stomach Cancer Surgery
Gastric Carcinoma, Gastroesophageal Junction Adenocarcinoma
Active, not recruitingPhase 2
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing conventional laparoscopy gastrectomy group (Port > 3) and reduced-port robotic group (Port ≤ 3) in people with Gastric Cancer, run by Yonsei University at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 12 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hyung Il Kim, Prof. (010-2556-4986, cairus@yuhs.ac), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of postoperative complications of Clavien-Dindo grade ≥ III within 30 days after surgery (time frame: postoperative 30 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07467174, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2026.